This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Sep 20;328(11):1041-1042.

doi: 10.1001/jama.2022.15268.

New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges

Thomas J Hwang^{1

2}, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliations

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Division of Urological Surgery, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 35984652
DOI: 10.1001/jama.2022.15268

New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges

Thomas J Hwang et al. JAMA. 2022.

. 2022 Sep 20;328(11):1041-1042.

doi: 10.1001/jama.2022.15268.

Authors

Thomas J Hwang^{1

2}, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Division of Urological Surgery, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 35984652
DOI: 10.1001/jama.2022.15268

No abstract available

PubMed Disclaimer

Similar articles

Value-Based Pricing and State Reform of Prescription Drug Costs.
Hwang TJ, Kesselheim AS, Sarpatwari A. Hwang TJ, et al. JAMA. 2017 Aug 15;318(7):609-610. doi: 10.1001/jama.2017.8255. JAMA. 2017. PMID: 28692713 No abstract available.
Fair global drug pricing.
Campbell JD, Kaló Z. Campbell JD, et al. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):581-583. doi: 10.1080/14737167.2018.1524296. Epub 2018 Sep 28. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 30215535 No abstract available.
International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ, Kesselheim AS. Rand LZ, et al. Value Health. 2021 Apr;24(4):473-476. doi: 10.1016/j.jval.2020.11.009. Epub 2020 Dec 31. Value Health. 2021. PMID: 33840424
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS, Avorn J, Sarpatwari A. Kesselheim AS, et al. JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. JAMA. 2016. PMID: 27552619 Review.
Healing an ailing pharmaceutical system: prescription for reform for United States and Canada.
Gaffney A, Lexchin J; US; Canadian Pharmaceutical Policy Reform Working Group. Gaffney A, et al. BMJ. 2018 May 17;361:k1039. doi: 10.1136/bmj.k1039. BMJ. 2018. PMID: 29773533 Review. No abstract available.

See all similar articles

Cited by

Pharmaceutical Purchasing: a Review of the Landscape and Implications for Antidotal Therapies.
Troger A, Burns MM. Troger A, et al. J Med Toxicol. 2023 Jul;19(3):262-267. doi: 10.1007/s13181-023-00943-5. Epub 2023 May 30. J Med Toxicol. 2023. PMID: 37249803 Free PMC article. Review.
Drivers of innovation value: simulation for new drug pricing evaluation based on system dynamics modelling.
Xing Q, Cheng W, Wang W, Jin C, Wang H. Xing Q, et al. Front Pharmacol. 2025 Jan 22;16:1474856. doi: 10.3389/fphar.2025.1474856. eCollection 2025. Front Pharmacol. 2025. PMID: 39911851 Free PMC article.
Drugs likely subject to Medicare negotiation, 2026-2028.
Dickson S, Hernandez I. Dickson S, et al. J Manag Care Spec Pharm. 2023 Mar;29(3):229-235. doi: 10.18553/jmcp.2023.29.3.229. J Manag Care Spec Pharm. 2023. PMID: 36840960 Free PMC article.
Association of Medicare eligibility with access to and affordability of care among older cancer survivors.
Kwon Y, Roberts ET, Degenholtz HB, Jacobs BL, Sabik LM. Kwon Y, et al. J Cancer Surviv. 2025 Aug;19(4):1431-1441. doi: 10.1007/s11764-024-01562-x. Epub 2024 Mar 23. J Cancer Surviv. 2025. PMID: 38520599 Free PMC article.
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Luo J, Feldman R, Callaway Kim K, Rothenberger S, Korytkowski M, Hernandez I, Gellad WF. Luo J, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2317886. doi: 10.1001/jamanetworkopen.2023.17886. JAMA Netw Open. 2023. PMID: 37307000 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems